Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
about
Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1)Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitorX-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitorsStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability.Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.Development and strategies of VEGFR-2/KDR inhibitors.A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.Selectivity and potency of cyclin-dependent kinase inhibitors.Synthesis and Anticancer Activity of 2-(Alkyl-, Alkaryl-, Aryl-, Hetaryl-)-[1,2,4]triazolo[1,5-c]quinazolinesInclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approachSouthwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancerDesign and Evaluation of Novel Antimicrobial and Anticancer Agents Among Tetrazolo[1,5-c]quinazoline-5-thione S-Derivatives.Structural characterization of proteins using residue environments.An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular DynamicsEnergetics of displacing water molecules from protein binding sites: consequences for ligand optimizationAutophagic action of new targeting agents in head and neck oncology.A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2.A computational protocol to evaluate the effects of protein mutants in the kinase gatekeeper position on the binding of ATP substrate analogues.Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors.Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules.Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil.In Silico Drug-Designing Studies on Flavanoids as Anticolon Cancer Agents: Pharmacophore Mapping, Molecular Docking, and Monte Carlo Method-Based QSAR Modeling.Tosylate salts of the anticancer drug lapatinib.Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In VivoIn Silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents
P2860
Q24307730-951437F0-B13D-4CAB-9CB3-AAAEF36E27BDQ27639528-BDB4BD96-7A71-4D3C-9EB4-6ABD05C94DA3Q27686685-C588D435-3BA5-40AC-AE3F-300EAD235426Q27853214-D8C8EC1D-EB42-4015-B1E7-31197F83BF37Q30847612-617A752F-08B8-4C59-8DC8-83EF7EEF1AEFQ31150794-AF406212-869E-4DDE-9161-48E4982B01C1Q34243088-A0CB4CF9-4D68-44E6-95BF-0422B37105C6Q34436101-FFE2CC25-83B9-4579-8021-41C1A536F777Q34611637-A01264EC-F54D-45A9-93CA-0B1EE24C4918Q34651981-A97FE611-DFAE-44C8-8698-6E0CFDA68E6AQ34801984-7FBCBC97-802B-4881-B4B1-480F50B63D13Q35045753-DB99CF81-281D-420A-9E6B-4156C7158DE4Q35565614-A713B3F1-9F3B-4510-AD85-65818E1FE43EQ35571704-42DC7AB5-A417-48D6-A8C5-BA3321C34981Q35926639-2A4F6735-1A45-47A0-BCD1-D2798A63A0F0Q36456386-14ADB510-2E22-4406-8A56-EA183D6EDC7BQ36743434-D48A76C7-C13F-4A0A-A5A2-6CB3678DD652Q36789994-603CEEA2-D3A0-4AC0-BFFD-D4FDA18DD1B2Q37409322-C79FAD1A-31B4-4528-826C-A1891DC728A5Q37439036-46250A1F-CAB0-4FA3-94F9-A661B8EAF217Q38028794-EFE0824F-6A4C-4DA3-A39C-F9146D269841Q38503202-A65AC1F7-31AF-4A42-8DC3-40046030DA73Q38794658-FD2D1381-BF0A-4F78-9BFD-5ECB526951BFQ38951478-45A8956A-C99C-4446-A902-2E65FC125E41Q39084077-D3773767-8C1D-4893-A72F-9C1EFE42475FQ43161207-A45D665C-CE5E-4759-A421-71D0FCE48E2DQ44564952-C4B7D5AA-D1AF-400B-8671-6C9F7832BA73Q46770101-B53EB5AC-7C0D-4F8F-B59B-0C1B0E5F2DD6Q54482784-86DAABF7-A62C-4AC5-9C26-A31FA1E27C4CQ58734645-FD88F7C7-57D7-42DB-9E23-90A22F2D70A8Q59121341-B7BF77FD-BA75-4436-A9DA-04772BA125FF
P2860
Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@ast
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@en
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@nl
type
label
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@ast
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@en
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@nl
prefLabel
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@ast
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@en
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@nl
P2093
P356
P1476
Binding mode of the 4-anilinoq ...... endent kinase 2 and p38 kinase
@en
P2093
L F Kuyper
L Shewchuk
P356
10.1021/JM990401T
P407
P577
2000-01-13T00:00:00Z